HCAR2 Antikörper (AA 200-228)

Produktnummer ABIN656596

Produktdetails anti-HCAR2 Antikörper

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Bindungsspezifität: AA 200-228

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HCAR2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Homologie: M

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This NIACR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 200-228 amino acids of human NIACR1.

Klon: RB31358

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: NIACR1 Antibody (Center) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, place the at -20 °C.

Haltbarkeit: 6 months

Details zu HCAR2

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Andere Bezeichnung: NIACR1 (HCAR2 Produkte)

Synonyme: GPR109A antikoerper, HCA2 antikoerper, HM74a antikoerper, HM74b antikoerper, NIACR1 antikoerper, PUMAG antikoerper, Puma-g antikoerper, Gpr109a antikoerper, Gpr109b antikoerper, HM74 antikoerper, Hcar2 antikoerper, PUMA-G antikoerper, Pumag antikoerper, mHM74b antikoerper, HCAR2 antikoerper, HCAR3 antikoerper, hydroxycarboxylic acid receptor 2 antikoerper, HCAR2 antikoerper, Hcar2 antikoerper, LOC527744 antikoerper

Hintergrund: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

Molekulargewicht: 41850

Gen-ID: 338442

NCBI Accession: NP_808219

UniProt: Q8TDS4